National registries of systemic treatment for psoriasis and the European 'Psonet' initiative

Dermatology

Volumn 218, Issue 4, 2009, Pages 347-356

  Lecluse, L L A ^a   Naldi, L ^b   Stern, R S ^c   Spuls, P I ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b OSPEDALI RIUNITI   (Italy)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Psoriasis registries; Systemic therapy, safety; Treatment outcome

Indexed keywords

ADALIMUMAB; ALEFACEPT; CYCLOSPORIN; CYCLOSPORIN A; EFALIZUMAB; ETANERCEPT; ETRETIN; FUMARIC ACID; INFLIXIMAB; METHOTREXATE; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ARTICLE; CHRONIC DISEASE; CLINICAL PRACTICE; DATA ANALYSIS; DISEASE REGISTRY; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; EUROPE; FOLLOW UP; FOOD AND DRUG ADMINISTRATION; FRANCE; GERMANY; HEALTH CARE ORGANIZATION; HUMAN; INCIDENCE; INFORMATION PROCESSING; INFORMED CONSENT; INTERNATIONAL COOPERATION; ISRAEL; ITALY; NETHERLANDS; PHOTOCHEMOTHERAPY; PHYSICIAN; PORTUGAL; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; PROGNOSIS; PSORIASIS; PUVA; QUALITY OF LIFE; SPAIN; SWEDEN; SYSTEMIC THERAPY; TREATMENT OUTCOME; UNITED KINGDOM;

EUROPE; HUMANS; MEDICAL RECORDS; PRODUCT SURVEILLANCE, POSTMARKETING; PSORIASIS; PUVA THERAPY; REGISTRIES;

EID: 67651111868     PISSN: 10188665     EISSN: None     Source Type: Journal    
DOI: 10.1159/000183757     Document Type: Article

References (21)

1. Farber EM, Nall ML: Epidemiology: natural history and genetics; in Roenigk HH, Maibach HI (eds): Psoriasis. New York, Dekker, 1998, pp 107-158.
2. Krueger G, Koo J, Lebwohl M, Menter A, Stern RS, Rolstad T: The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey. Arch Dermatol 2001; 137: 280-284.
3. Rapp SR, Feldman SR, Exum ML, Fleischer AB Jr, Reboussin DM: Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol 1999; 41: 401-407.
4. Stern RS: A promising step forward in psoriasis therapy. JAMA 2003; 290: 3133-3135.
5. Katz KA: 'Biologics': a clinically meaningless term. Br J Dermatol 2006; 154: 809-812.
6. Naldi L: The search for effective and safe disease control in psoriasis. Lancet 2008; 371: 1311-1312.
7. Elder JT: Psoriasis clinical registries, genetics, and genomics. Ann Rheum Dis 2005; 64(suppl 2):ii106-ii107.
8. Stern RS, Nijsten T: Insuring rapid and robust safety assessment. J Invest Dermatol 2004; 122: 857-858. (Pubitemid 38471363)
9. Schmitt-Egenolf M: Psoriasis therapy in real life: the need for registries. Dermatology 2006; 213: 327-330.
10. Zink A, Askling J, Dixon WG, Klareskog L, Silman AJ, Symmons DP: European biologics registers - methodology, selected results, and perspectives. Ann Rheum Dis 2008, E-pub ahead of print.
11. Black N, Barker M, Payne M: Cross-sectional survey of multicentre databases in the United Kingdom. BMJ 2004; 328: 1478. (Pubitemid 38829911)
12. Gruppo di lavoro Psocare: Trattamento della psoriasi con farmaci sistemici in Italia. Resoconto sull'andamento del programma Psocare; 7 A.D.
13. Psocare: 2008. www.psocare.it.
14. Schmitt-Egenolf M: PsoReg - the Swedish registry for systemic psoriasis treatment. The registry's design and objectives. Dermatology 2007; 214: 112-117.
15. Biobadaser: 2008. www.biobadaser.ser.es.
16. BADBIR: 2008. www.badbir.org.
17. Tubach F, Salmon-Ceron D, Ravaud P, Mariette X: The RATIO observatory: French registry of opportunistic infections, severe bacterial infections, and lymphomas complicating anti-TNFalpha therapy. Joint Bone Spine 2005; 72: 456-460. (Pubitemid 41821398)
18. Berends MA, Driessen RJ, Langewouters AM, Boezeman JB, van de Kerkhof PC, de Jong EM: Etanercept and efalizumab treatment for high-need psoriasis. Effects and side effects in a prospective cohort study in outpatient clinical practice. J Dermatol Treat 2007; 18: 76-83.
19. Driessen RJ, Berends MAM, van de Kerkhof PCM, de Jong EMGJ: 'Biologics' in de praktijk: prospectieve cohortmonitoring van high need psoriasispatienten. Ned Tijdschr Dermatol Venereol 2007; 17: 162-166.
20. de Groot M, Appelman M, Spuls PI, de Rie MA, Bos JD: Initial experience with routine administration of etanercept in psoriasis. Br J Dermatol 2006; 155: 808-814. (Pubitemid 44352563)
21. Agency for Healthcare Research and Quality (AHRQ): Summary of registries for evaluating patient outcomes: a user's guide. http:// effectivehealthcare. ahrq.gov/healthInfo.cfm? infotype=nr&DocID=12&ProcessID=21.